Advaxis and Merck collaborate to study novel cancer treatments

August 25, 2014 4:01 PM

16 0

The two companies will join together to evaluate the combination of ADXS-PSA/pembrolizumab to treat prostate cancer.

Advaxis and Merck collaborate to study the combination of ADXS-PSA, Advaxis’s Lm-LLO cancer immunotherapy, and pembrolizumab, Merck’s investigational anti PD-1 antibody. Advaxis is a clinical-stage biotechnology company that develops cancer immunotherapies. The clinical trial will examine the safety...

Read more

To category page